Btg Share Discussion Threads

[fhmktg] 08/11/2017 16:30

Roll on Tuesday...let's get it over.

[ugandalad] 07/11/2017 09:33

As a long term holder who is doing very well from this speculative share there seems to be an over reaction to the Legal action decision which first came to light on 20th September 2017. 10 days before this the share price was at 705p on the 11 days preceding the announcement the price dropped to 665p on the day of the announcement. Since then it has climbed steadily with the implications of the judgement known to the market. The latest drop of around 6% puts the price back about 3 weeks. As this share does fluctuate between hard news there is nothing unusual. Given the changes in the company since I first invested I see the process as on going. The CEO is managing the process not the share price but if it rises to 786 I will have doubled my money ignoring the profits I have already banked. I think this team is quite visionary operating in a difficult industry so expect the odd b*lls up. IMHO

[semper vigilans] 07/11/2017 07:48

Bring it on!

[bargainbob] 07/11/2017 07:32

Ok where do we sign.

[fhmktg] 07/11/2017 07:16

OK!£10.50 and it's a deal!

[bargainbob] 07/11/2017 02:58

£9 a share they can have it.

[fhmktg] 06/11/2017 23:36

£12 a share and they can have it!

[cockneytrader] 06/11/2017 17:19

Very poor show today. And these people pay themselves millions, and can't perform. This is not a one off, many millions down the drain in previous news flow, all home grown.

I am afraid to have to inform you all that BTG is probably better off in foreign hands, we just don't seem to have the capacity for big business.

[a1ord53] 06/11/2017 13:37

I am being writing here many years , that Dame and her Rolf just not good enough and should go.
Penalty paid for Biocompatibles, wrong management build own sales Varethena team instead of licence or partner with big ones.Vistogard - lost deal.
Although for today move is to blame insiders, who over bought on insiders news and sold of today scared to death .

[ugandalad] 06/11/2017 13:00

Investor Chronicle just posted update after this mornings announcements stating they believe shares undervalued and are stil buyers.!!

[allonblack] 06/11/2017 12:23

I think the company has said there are approx 750k below the knee treatments in US. At $1.6k a treatment that's a market that's worth $1.2bn. So to be a $100m rev biz Varathena would need a 10% market share.

[cockneytrader] 06/11/2017 12:18

Allonblack, I take you use the product?

[allonblack] 06/11/2017 12:08

Max dosage is not a guide to how much gets used and shelf life is irrelevant. Typically the doctor will use 3-5ml and that's it. The can gets used over the day on several patients. 15ml would be used very rarely for above the knee main vein. The numbers you are quoting aren't relevant to the news this morning. Varithena may not succeed. But it will be doctors preferring laser treatment to foam. It will have nothing to do with the cost of the can or its shelf life.

[cockneytrader] 06/11/2017 11:59

The maximum number of treatments from one canister, in best case is 15 treatments at 3ml minimum uptake. In these clinics Varithena may be an option.

[cockneytrader] 06/11/2017 11:39

Varithena has never been up and running. Look at the pitiful revenues.

One canister contains 45 ml of usable foam of which 15ml is the maximum permissible for one vein. Therefore one canister per three veins. That's $1000 of foam per treatment excluding all other costs.

And btw, the canister has only a 30 day shelf life.

Varithena has cost shareholders over £250 million to date and is most definitely not up and running.

[allonblack] 06/11/2017 11:19

Varithena is up and running again. I'm not sure where you get the view that its now a write off.Most treatments eg below the knee only need 2/3ml. Most people can be treated in this bracket. The issue is now whether Drs treat using laser or foam not Varithena specific. In fact doctors now have an incentive to use Varithena vs own foam as the fee is 10x higher. Varithena is now more likely to be a 100m biz again as a result of this pricing and def not a write off. The loss of Vistogard is a 2% downgrade to 2020 earnings that was priced in September. Right reaction is probably -4% today after +4% Friday and then higher.

[bargainbob] 06/11/2017 10:54

It was said that to gain growth it needed a joint partnership.
Louise will learn her lesson , just because you have a better mouse trap does not mean people will follow your path.

[gregsc] 06/11/2017 10:43

Apparently Welstat's complaint was that the sales team was too small to be effective. The Judge agreed. Maybe this is also the problem with the varicose vein treatment.

[gregmorg] 06/11/2017 10:22

Suspect the code pricing is based upon per procedure

[bill hunt] 06/11/2017 10:13

Next Tuesday should give more insight with reporting and Q andA session. Until then we are just guessing.

[ashehzi] 06/11/2017 10:00

Though the news is old, but same one,
hxxp://www.proactiveinvestors.co.uk/companies/news/184282/btg-shares-fall-as-its-ordered-to-pay-us558mln-in-damages-in-drug-distrubution-dispute-184282.html

still price at 900p from Numis Securities

[cockneytrader] 06/11/2017 10:00

The cost of treatment is approx $1500-3000 per procedure. Costs met by the insurer come in at the lower end. If the numbers of treatments don't grow significantly at any time soon, they will have to write Varithena off.

Btg are fully valued for now. The loss of the Welstat revenue, several million per year, and was growing. The loss millions from Lemtrada coming off patent. This is not a good news day and £55 million to cough up.

I am surprised the market has been so kind.

[gregmorg] 06/11/2017 09:51

Noted on Codes, but my question is on the application of payment for multiple veins.

Are these rules applicable to multiple veins in the same leg or does it actually apply across both legs?

Previous suggested Varithena pricing policies, that I have been aware of, have been on the basis of a single leg and, for all sorts of medical reasons, only one leg could
be treated at a time/session with a break of some weeks-if not months before the other leg could be treated. Each leg had been regarded as a separate medical event!

So does the Code pricing structure adhere to this one leg principle or does multiple vein treatment actually apply across both legs?

[bargainbob] 06/11/2017 09:42

Is a treatment , one leg at a time . Could make a big difference on how you read the update.

4 legs can you help lol.